Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Chronic lung disease treatment in New Zealand often not consistent with international guidelines

Clocktower.

Tuesday, 19 December 2017 10:53am

LianneParkinJackDummerimage
Dr Lianne Parkin and Dr Jack Dummer, Dunedin School of Medicine.

University of Otago researchers have found that the treatment of chronic obstructive pulmonary disease (COPD) in New Zealand frequently does not conform to international guidelines.

The disease, often known as emphysema and usually caused by smoking, is a common cause of hospital admissions and death, and affects an estimated 100,000 people in New Zealand.

The mainstays for COPD treatment are inhaled long-acting bronchodilators – long-acting beta-2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs).

In a nationwide study just published online in the journal Respirology, University of Otago researchers from the Pharmacoepidemiology Research Network followed New Zealanders with COPD from the time they first started a LABA and/or LAMA inhaler and examined their treatment patterns over time.

“We observed complex patterns of therapy: people switched between different combinations of LABA, LAMA, and steroid inhalers, and periods without treatment were common,” says Dr Jack Dummer, respiratory physician and study co-author.

“Use of long-term steroid inhalers was also inconsistent with guidelines: this type of treatment was common, and people with few flare-ups of their disease were over-treated with inhaled steroids, while people with more frequent flare-ups were under-treated.”

Dr Dummer says guidelines issued by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommend the initial use of a LABA or LAMA inhaler in people with COPD who have more than occasional symptoms, and the addition of a second long-acting bronchodilator in those with persistent symptoms. For people with frequent flare-ups, the addition of a long-term inhaled steroid may reduce the number of flare-ups, but inhaled steroids have no benefit in the remaining patients with COPD.

“Recent studies in several countries have found that prescribing practice does not adhere to international or national COPD treatment guidelines”, says lead author, Dr Lianne Parkin.

“However, it was not known what was happening in New Zealand.”

The study was based on anonymised national pharmaceutical dispensing and health data for 83,435 New Zealanders aged 45 years and over who started LABA and/or LAMA therapy for treatment of COPD between February 2006 and December 2013, and was funded by a Strategic Research Grant from the Department of Preventive and Social Medicine.

For more information, contact:

Dr Lianne Parkin
Senior Lecturer
Department of Preventive and Social Medicine
Dunedin School of Medicine
University of Otago
Email: lianne.parkin@otago.ac.nz
Tel: +64 3 479 8425 or +64 21 0268 1983

Dr Jack Dummer
Senior Lecturer
Department of Medicine
Dunedin School of Medicine
University of Otago
Email: jack.dummer@otago.ac.nz
Tel: +64 21 2048494

Publication details:
Parkin L, Barson D, Zeng J, Horsburgh S, Sharples K, Dummer J. Patterns of use of long-acting bronchodilators in people with COPD: A nationwide follow-up study of new users in New Zealand. Respirology 2017 doi:10.1111/resp.13235

A list of Otago experts available for media comment is available elsewhere on this website.

Electronic addresses (including email accounts, instant messaging services, or telephone accounts) published on this page are for the sole purpose of contact with the individuals concerned, in their capacity as officers, employees or students of the University of Otago, or their respective organisation. Publication of any such electronic address is not to be taken as consent to receive unsolicited commercial electronic messages by the address holder.